+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Atherosclerosis after Coronary Artery Bypass Surgery: Results of Recent Studies and Recommendations Regarding Prevention

      , , ,


      S. Karger AG

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Atherosclerosis is the most frequent cause of occlusion of aortocoronary saphenousvein grafts between 5 and 10 years after coronary artery bypass surgery. The typical atherosclerotic plaque appears between 1 and 3 years after operation and, at a mean of 5 years, histologic changes of atherosclerosis are present in 21 % of grafts and in 27% of patients. Only approximately 60% of saphenous vein grafts remain patent at repeat angiography between 10 and 12 years after bypass surgery; 45% of patent grafts show atherosclerotic changes at angiography and 43% of patients show evidence of atherosclerosis in one or more saphenous vein grafts. We do not know whether the development or the progression of these atherosclerotic changes can be modified; however, the data currently available suggest that the administration of platelet inhibitors and/or of lipid lowering agents offer two promising avenues of investigation in patients undergoing aortocoronary saphenous vein bypass surgery. Until this has been carefully studied, the internal mammary artery should remain the preferred conduit for aortocoronary bypass grafting, whenever possible.

          Related collections

          Author and article information

          S. Karger AG
          11 November 2008
          : 73
          : 4-5
          : 259-268
          Montreal Heart Institute and Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada
          174019 Cardiology 1986;73:259–268
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Original Paper

          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology


          Comment on this article